This is a technical filing with no immediate stock impact, but the registration of ~15.5M shares for resale (roughly equal to current shares outstanding) creates a significant overhang. Monitor for actual selling by holders of the Orphai merger consideration and PIPE shares. Trading volume and any subsequent prospectus supplements will indicate if/when holders begin to monetize.
Price Chart
Executive Summary
Quince Therapeutics filed Amendment No. 1 to its S-3 shelf registration solely to add Exhibit 5.1 (Cooley LLP legal opinion). The S-3 registers for resale up to 15,470,099 shares of common stock, comprised of shares and conversion/exercise shares from the May 2026 Orphai Therapeutics acquisition and concurrent PIPE. No new primary offering or capital raise is being conducted — this is a registration of existing shares for resale by selling stockholders.
Key Facts
- Amendment No. 1 to Form S-3 (File No. 333-297903) filed solely to file Exhibit 5.1 legal opinion
- Registers up to 15,470,099 shares of common stock for resale by selling stockholders
- Shares include 162,971 Acquisition Shares, 3,489,281 Acquisition Conversion Shares, 570,169 Acquisition Warrant Shares, 7,498,447 PIPE Conversion Shares, and 3,749,231 PIPE Warrant Shares
- All registered shares derive from merger consideration (Orphai Therapeutics acquisition) and May 2026 PIPE financing
- No new capital being raised for the company — no dilution from this filing itself
- SEC registration fee estimated at $38,600; total estimated expenses $498,600
Financial Impact
No capital raise for the company. Up to 15.5M shares (vs ~16.3M shares outstanding as of May 4, 2026) potentially entering the market via resale, representing material potential overhang. Pre-revenue clinical-stage biotech with $28M market cap.
Risk Factors
- The registered shares represent ~95% of current shares outstanding creating a large overhang even if only partially sold
- Pre-revenue company with $28M market cap and multiple recent financings suggests ongoing cash needs could lead to additional dilutive transactions
- Cross-filing context shows May 2026 merger and PIPE, indicating a complex capital structure with multiple convertible instruments
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-3/A Filing (Primary) | 0001193125-26-333764 |
| Document: d112732dex51.htm | 0001193125-26-333764 |
| Document: 0001193125-26-333764-index-headers.html | 0001193125-26-333764 |
| Document: 0001193125-26-333764-index.html | 0001193125-26-333764 |
| Document: 0001193125-26-333764.txt | 0001193125-26-333764 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 4, 2026 28d ago | 8-K | $31.32 $28.59 | ▲ +8.72% | ▲ +7.51% | $30.67 (+2.08%) |
Aug 25, 2026 5w ago | EFFECT | $30.93 $32.11 | ▼ −3.82% | ▼ −4.35% | $30.67 (+0.84%) |
Aug 14, 2026 7w ago | 8-K | $31.34 awaiting T+5 | awaiting T+5 | — | $30.67 (−2.14%) |
Aug 14, 2026 7w ago | Press Release | $31.34 awaiting T+5 | awaiting T+5 | — | $30.67 (−2.14%) |
Aug 5, 2026 8w ago | S-3/A | $28.88 $31.26 | ▲ +8.24% | ▲ +7.89% | $30.67 (+6.20%) |
Jun 11, 2026 16w ago | 3 | $0.9337 $0.9451 | ▲ +1.22% | ▲ +0.55% | $30.67 (+3184.78%) |
May 18, 2026 19w ago | 8-K | $19.90 $24.00 | ▲ +20.60% | ▲ +18.99% | $30.67 (+54.12%) |
Apr 27, 2026 22w ago | DEFA14A | $24.60 $24.60 | · 0.00% | ▼ −1.70% | $30.67 (+24.67%) |
Apr 9, 2026 25w ago | 8-K | $1.24 $1.34 | ▲ +8.06% | ▲ +4.88% | $30.67 (+2373.39%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access